Abstract

Pregnancy in women with sickle cell disease (SCD) is associated with increased maternal and fetal morbidity and mortality. Outcomes vary widely owing to methodological limitations of clinical studies, but overall, hypertensive disorders of pregnancy, venothromboembolism, poor fetal growth, and maternal and perinatal mortality are increased globally. Few therapeutic interventions have been explored other than prophylactic and selective transfusion therapy. Unfortunately, existing data are limited, and it remains unclear whether prophylactic use of chronic transfusions will improve pregnancy outcomes. Management of pregnant women with SCD is best accomplished with a multidisciplinary team that includes a sickle cell expert and an obstetrician familiar with high-risk pregnancies. Women with SCD should have individualized care plans that outline management of acute pain and guidelines for transfusion therapy. Neonates require close monitoring for neonatal abstinence syndrome and hemolytic disease of the newborn. Ideally all young women with SCD will have a "reproductive life plan" developed as a component of preconception counseling and health promotion. Research leading to improved pregnancy management focused on diminishing adverse maternal and neonatal outcomes is overdue. International collaborations should be considered to improve subject recruitment and foster timely completion of clinical trials. Additional therapeutic interventions outside of transfusion therapy should be explored.

References

References
1.
Chang
JN
,
Magann
EF
,
Novotny
SA
, et al
.
Maternal/perinatal outcome in women with sickle cell disease: a comparison of two time periods
.
South Med J
.
2018
;
111
(
12
):
742
-
745
.
2.
Asare
EV
,
Olayemi
E
,
Boafor
T
, et al
.
Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting
.
Am J Hematol
.
2017
;
92
(
9
):
872
-
878
.
3.
Afolabi
BB
,
Oladipo
OO
,
Akanmu
AS
, et al
.
Volume regulatory hormones and plasma volume in pregnant women with sickle cell disorder
.
J Renin Angiotensin Aldosterone Syst
.
2016
;
17
(
3
):
1470320316670444
.
4.
Baptista
LC
,
Costa
ML
,
Ferreira
R
, et al
.
Abnormal expression of inflammatory genes in placentas of women with sickle cell anemia and sickle hemoglobin C disease
.
Ann Hematol
.
2016
;
95
(
11
):
1859
-
1867
.
5.
Oteng-Ntim
E
,
Ayensah
B
,
Knight
M
,
Howard
J
.
Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease
.
Br J Haematol
.
2015
;
169
(
1
):
129
-
137
.
6.
Boafor
TK
,
Olayemi
E
,
Galadanci
N
, et al
.
Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis
.
BJOG
.
2016
;
123
(
5
):
691
-
698
.
7.
Smith
JA
,
Espeland
M
,
Bellevue
R
,
Bonds
D
,
Brown
AK
,
Koshy
M
.
Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease
.
Obstet Gynecol
.
1996
;
87
(
2
):
199
-
204
.
8.
Henderson
JT
,
Thompson
JH
,
Burda
BU
,
Cantor
A
.
Preeclampsia screening: evidence report and systematic review for the US Preventive Services Task Force
.
JAMA
.
2017
;
317
(
16
):
1668
-
1683
.
9.
Bibbins-Domingo
K
,
Grossman
DC
,
Curry
SJ
, et al
;
US Preventive Services Task Force
.
Screening for preeclampsia: US Preventive Services Task Force recommendation statement
.
JAMA
.
2017
;
317
(
16
):
1661
-
1667
.
10.
Prophet
J
,
Kelly
K
,
Domingo
J
, et al
.
Severe pre-eclampsia among pregnant women with sickle cell disease and HIV
.
Pregnancy Hypertens
.
2018
;
11
:
87
-
91
.
11.
Thame
MM
,
Singh-Minott
I
,
Osmond
C
,
Melbourne-Chambers
RH
,
Serjeant
GR
.
Pregnancy in sickle cell-haemoglobin C (SC) disease. A retrospective study of birth size and maternal weight gain
.
Eur J Obstet Gynecol Reprod Biol
.
2016
;
203
:
16
-
19
.
12.
Thame
MM
,
Osmond
C
,
Serjeant
GR
.
Fetal growth in women with homozygous sickle cell disease: an observational study
.
Eur J Obstet Gynecol Reprod Biol
.
2013
;
170
(
1
):
62
-
66
.
13.
Thame
M
,
Lewis
J
,
Trotman
H
,
Hambleton
I
,
Serjeant
G
.
The mechanisms of low birth weight in infants of mothers with homozygous sickle cell disease
.
Pediatrics
.
2007
;
120
(
3
):
e686
-
e693
.
14.
Lari
NF
,
DeBaun
MR
,
Oppong
SA
.
The emerging challenge of optimal blood pressure management and hypertensive syndromes in pregnant women with sickle cell disease: a review
.
Expert Rev Hematol
.
2017
;
10
(
11
):
987
-
994
.
15.
Roberge
S
,
Bujold
E
,
Nicolaides
KH
.
Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis
.
Am J Obstet Gynecol.
2018
;
218
(
3
):
287
-
293.e1
.
16.
Tolcher
MC
,
Chu
DM
,
Hollier
LM
, et al
.
Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia
.
Am J Obstet Gynecol
.
2017
;
217
(
3
):
365.e1
-
365.e8
.
17.
American College of Obstetricians and Gynecologists, ACOG Committee Opinion Number 741, June 2018.
18.
Royal College of Obstetricians & Gynaecologists. Management of sickle cell disease in pregnancy (Green-top Guideline No 61). https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_61.pdf. Accessed 22 July 2019
.
19.
Costa
VM
,
Viana
MB
,
Aguiar
RA
.
Pregnancy in patients with sickle cell disease: maternal and perinatal outcomes
.
J Matern Fetal Neonatal Med
.
2015
;
28
(
6
):
685
-
689
.
20.
Naik
RP
,
Streiff
MB
,
Lanzkron
S
. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.
J Thromb Thrombolysis.
2013
;
35
(
3
):
352
-
358
.
21.
McCowan
LM
,
Thompson
JM
,
Taylor
RS
,et al
;
SCOPE Consortium. Clinical prediction in early pregnancy of infants small for gestational age by customised birthweight centiles: findings from a healthy nulliparous cohort
.
PLoS One.
2013
;
8
(
8
):
e70917
.
22.
Sun
PM
,
Wilburn
W
,
Raynor
BD
,
Jamieson
D
.
Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia
.
Am J Obstet Gynecol.
2001
;
184
(
6
):
1127
-
1130
.
23.
Meeks
D
,
Robinson
SE
,
Macleod
D
,
Oteng-Ntim
E
.
Birth weights in sickle cell disease pregnancies: a cohort study
.
PLoS One.
2016
;
11
(
10
):
e0165238
.
24.
Alayed
N
,
Kezouh
A
,
Oddy
L
,
Abenhaim
HA
.
Sickle cell disease and pregnancy outcomes: population-based study on 8.8 million births
.
J Perinat Med.
2014
;
42
(
4
):
487
-
492
.
25.
Rizk
S
,
Pulte
ED
,
Axelrod
D
,
Ballas
SK
.
Perinatal maternal mortality in sickle cell anemia: two case reports and review of the literature
.
Hemoglobin.
2017
;
41
(
4-6
):
225
-
229
.
26.
Hassell
K.
Pregnancy and sickle cell disease
.
Hematol Oncol Clin North Am.
2005
;
19
(
5
):
903
-
916
.
27.
Cardosa
D
,
Ridout
A
,
Nanda
S
,
Howard
J
,
Robinson
SE
,
Oteng-Ntim
E
.
Maternal sickle cell disease and twin pregnancy: a case series and review of the literature
.
Hematology.
2019
;
24
(
1
):
148
-
158
.
28.
Odukogbe
AA
,
Aken’Ova
YA
,
Ojengbede
OA
.
Outcome of twin pregnancies in patients with haemoglobinopathies—case reports
.
West Afr J Med.
1999
;
18
(
3
):
217
-
219
.
29.
Litos
M
,
Sarris
I
,
Bewley
S
,
Seed
P
,
Okpala
I
,
Oteng-Ntim
E
.
White blood cell count as a predictor of the severity of sickle cell disease during pregnancy
.
Eur J Obstet Gynecol Reprod Biol
.
2007
;
133
(
2
):
169
-
172
.
30.
Morris
JS
,
Dunn
DT
,
Poddar
D
,
Serjeant
GR
.
Haematological risk factors for pregnancy outcome in Jamaican women with homozygous sickle cell disease
.
Br J Obstet Gynaecol
.
1994
;
101
(
9
):
770
-
773
.
31.
Sarris
I
,
Litos
M
,
Bewley
S
,
Okpala
I
,
Seed
P
,
Oteng-Ntim
E
.
Platelet count as a predictor of the severity of sickle cell disease during pregnancy
.
J Obstet Gynaecol.
2008
;
28
(
7
):
688
-
691
.
32.
Kuo
K
,
Caughey
AB
.
Contemporary outcomes of sickle cell disease in pregnancy
.
Am J Obstet Gynecol.
2016
;
215
(
4
):
505e1
-
505e5
.
33.
ACOG Committee on Obstetrics
.
ACOG practice bulletin no. 78: hemoglobinopathies in pregnancy
.
Obstet Gynecol.
2007
;
109
(
1
):
229
-
237
.
34.
Howard
RJ
,
Tuck
SM
,
Pearson
TC
.
Optimal haematocrit and haemoglobin S levels in pregnant women with sickle cell disease
.
Clin Lab Haematol
.
1995
;
17
(
2
):
157
-
161
.
35.
Howard
J
,
Oteng-Ntim
E
.
The obstetric management of sickle cell disease
.
Best Pract Res Clin Obstet Gynaecol.
2012
;
26
(
1
):
25
-
36
.
36.
American College of Obstetricians and Gynecologists’ Committee on Practice
.
Practice bulletin no. 162: prenatal diagnostic testing for genetic disorders
.
Obstet Gynecol
.
2016
;
127
(
5
):
e108
-
e122
.
37.
US Department of Health and Human Services; National Institutes of Health, National Heart, Ling and Blood Institute. Evidence-based management of sickle cell disease 2014. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease. Accessed 22 July 2019
.
38.
Nnoli
A
,
Seligman
NS
,
Dysart
K
,
Baxter
JK
,
Ballas
SK
.
Opioid utilization by pregnant women with sickle cell disease and the risk of neonatal abstinence syndrome
.
J Natl Med Assoc
.
2018
;
110
(
2
):
163
-
168
.
39.
Naik
RP
,
Lanzkron
S
.
Baby on board: what you need to know about pregnancy in the hemoglobinopathies
.
Hematology Am Soc Hematol Educ Program.
2012
;
2012
:
208
-
214
.
40.
Jackson
B
,
Fasano
R
,
Roback
J
.
Current evidence for the use of prophylactic transfusion to treat sickle cell disease during pregnancy
.
Transfus Med Rev.
2018
;
32
(
4
):
220
-
224
.
41.
Attal
JP
,
Lafay-Pillet
MC
,
Taurelle
R
.
The value of systematic prophylactic blood transfusions in the outcome of pregnancies in patients with severe sickle cell anemia. Study of 63 deliveries in Guadeloupe
.
J Gynecol Obstet Biol Reprod (Paris).
1987
;
16
(
6
):
787
-
793
.
42.
Ribeil
JA
,
Labopin
M
,
Stanislas
A
, et al
.
Transfusion-related adverse events are decreased in pregnant women with sickle cell disease by a change in policy from systematic transfusion to prophylactic oxygen therapy at home: a retrospective survey by the international sickle cell disease observatory
.
Am J Hematol.
2018
;
93
(
6
):
794
-
802
.
You do not currently have access to this content.